Drug DevelopmentRisvodetinib shows over 25 times stronger inhibition of c-Abl, with modifications enhancing brain penetration and selectivity, potentially leading to groundbreaking treatments in Parkinson's disease.
Financial StabilityWith sufficient cash on hand and a recent At-The-Market offering, the company has a stable financial outlook, allowing it to reach important development milestones without the immediate need for additional funding.
Regulatory MilestoneIkT-001Pro has an improved safety and tolerability profile compared to imatinib, possibly reducing gastrointestinal side effects and enhancing patient adherence to treatment, marking a significant step in cancer care.